Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Bought by Man Group plc

Man Group plc increased its holdings in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 80.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 288,689 shares of the company's stock after purchasing an additional 128,317 shares during the quarter. Man Group plc owned approximately 0.20% of Adaptive Biotechnologies worth $1,731,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. SG Americas Securities LLC lifted its stake in Adaptive Biotechnologies by 11.7% in the fourth quarter. SG Americas Securities LLC now owns 45,944 shares of the company's stock valued at $275,000 after buying an additional 4,799 shares during the last quarter. Impact Partnership Wealth LLC raised its stake in shares of Adaptive Biotechnologies by 8.8% during the fourth quarter. Impact Partnership Wealth LLC now owns 19,078 shares of the company's stock worth $114,000 after purchasing an additional 1,539 shares during the last quarter. KBC Group NV purchased a new stake in shares of Adaptive Biotechnologies during the fourth quarter worth approximately $50,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Adaptive Biotechnologies by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 31,292 shares of the company's stock worth $188,000 after purchasing an additional 2,928 shares during the last quarter. Finally, Rhumbline Advisers raised its stake in shares of Adaptive Biotechnologies by 3.0% during the fourth quarter. Rhumbline Advisers now owns 181,202 shares of the company's stock worth $1,086,000 after purchasing an additional 5,361 shares during the last quarter. Hedge funds and other institutional investors own 99.17% of the company's stock.

Insider Buying and Selling

In related news, CEO Chad M. Robins sold 117,351 shares of Adaptive Biotechnologies stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $6.98, for a total value of $819,109.98. Following the completion of the sale, the chief executive officer now owns 2,814,350 shares in the company, valued at approximately $19,644,163. The trade was a 4.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Robert Hershberg sold 53,000 shares of Adaptive Biotechnologies stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $7.59, for a total transaction of $402,270.00. Following the completion of the transaction, the director now directly owns 69,690 shares of the company's stock, valued at approximately $528,947.10. This represents a 43.20% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 358,754 shares of company stock worth $2,584,806. Insiders own 6.40% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Morgan Stanley upped their price target on Adaptive Biotechnologies from $7.00 to $9.00 and gave the stock an "equal weight" rating in a research note on Monday, May 5th. Piper Sandler restated an "overweight" rating and set a $13.00 price target (up previously from $11.00) on shares of Adaptive Biotechnologies in a research note on Tuesday, May 6th. The Goldman Sachs Group upped their price objective on Adaptive Biotechnologies from $9.00 to $10.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Finally, Scotiabank upped their price objective on Adaptive Biotechnologies from $10.00 to $12.00 and gave the stock a "sector outperform" rating in a report on Thursday, February 13th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Adaptive Biotechnologies currently has a consensus rating of "Moderate Buy" and a consensus price target of $9.83.

Adaptive Biotechnologies Price Performance

NASDAQ ADPT traded up $0.38 during mid-day trading on Thursday, hitting $9.53. The company's stock had a trading volume of 506,541 shares, compared to its average volume of 1,574,898. Adaptive Biotechnologies Co. has a 52-week low of $2.99 and a 52-week high of $10.28. The stock's fifty day simple moving average is $8.27 and its two-hundred day simple moving average is $7.40. The firm has a market capitalization of $1.45 billion, a P/E ratio of -8.75 and a beta of 1.75.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.28) by $0.08. The company had revenue of $52.44 million for the quarter, compared to analyst estimates of $42.13 million. Adaptive Biotechnologies had a negative net margin of 89.12% and a negative return on equity of 64.65%. The business's quarterly revenue was up 25.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.33) earnings per share. On average, equities analysts forecast that Adaptive Biotechnologies Co. will post -0.92 earnings per share for the current fiscal year.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.